AngioDynamics (AngioDynamics) ROCE % : -14.05% (As of Feb. 2024)

View and export this data going back to 2004. Start your Free Trial

What is AngioDynamics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. AngioDynamics's annualized ROCE % for the quarter that ended in Feb. 2024 was -14.05%.

AngioDynamics ROCE % Historical Data

The historical data trend for AngioDynamics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics ROCE % Chart

AngioDynamics Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

ROCE %

Get a 7-Day Free Trial

-1.36

-25.61

-6.72

-5.96

-11.16

AngioDynamics Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
ROCE %	Get a 7-Day Free Trial															-4.45	-30.79	-8.79	-6.26	-14.05

AngioDynamics ROCE % Calculation

AngioDynamics's annualized ROCE % for the fiscal year that ended in May. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: May. 2023 )		(A: May. 2022 )		(A: May. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: May. 2023 )		(A: May. 2022 )		(A: May. 2023 )
	=	-51.735	/	( ( (552.751 - 74.324)	+	(532.637 - 83.825) )	/ 2 )
	=	-51.735	/	( (478.427	+	448.812)	/ 2 )
	=	-51.735	/	463.6195
	=	-11.16 %

AngioDynamics's ROCE % of for the quarter that ended in Feb. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Feb. 2024 )		(Q: Nov. 2023 )		(Q: Feb. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Feb. 2024 )		(Q: Nov. 2023 )		(Q: Feb. 2024 )
	=	-46.392	/	( ( (499.623 - 78.037)	+	(324.842 - 85.874) )	/ 2 )
	=	-46.392	/	( ( 421.586	+	238.968 )	/ 2 )
	=	-46.392	/	330.277
	=	-14.05 %

(1) Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

AngioDynamics (NAS:ANGO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

AngioDynamics ROCE % Related Terms

Thank you for viewing the detailed overview of AngioDynamics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

AngioDynamics (AngioDynamics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (NAS:ANGO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

UG2:Germany

Address

14 Plaza Drive, Latham, NY, USA, 12110

Website

https://www.angiodynamics.com

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, the company derives a majority of its revenue from the United States.

Executives

Lorinda Burgess	director	22 WEST FRONTAG ROAD, NORTHBROOK IL 60093
Karen A Licitra	director	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael E Tarnoff	director	C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Scott Centea	officer: SVP/GM, VIT	C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Dave Helsel	officer: SVP Global Operations and R&D	400 WOOD ROAD, BRAINTREE MA 02184
Laura Piccinini	officer: SVP International	C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110
Stephen A Trowbridge	officer: SVP and General Counsel	14 PLAZA DRIVE, LATHAM NY 120110
James C Clemmer	director, officer: President and CEO	COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Wesley Johnson	director
Chad Thomas Campbell	officer: SVP/GM, Vascular Access	140 POKANOKET PATH, WRENTHAM MA 02093
Warren Jr Nighan	officer: SVP Quality and Regulatory	ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Richard C Rosenzweig	officer: SVP and General Counsel	C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kevin J Gould	director	247 WASHINGTON STREET, DUXBURY MA 02332
Brent J. Boucher	officer: SVP and GM of Oncology	14 PLAZA DRIVE, LATHAM NY 12110
Michael Greiner	officer: EVP and CFO	C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421